In this exclusive interview with BioPharma BoardRoom, Mike Kadan, Chief Operating Officer of Vector BioMed, shares how the company is reimagining viral vec...
CEO Paul Hudson: Confidence in Full-Year Outlook Paul Hudson, Chief Executive Officer: “We had a strong start in 2025 with sales growth of 9.7%, b...
- Recorded Q1’25 consolidated revenue of KRW 1.3 trillion - Recorded Q1’25 consolidated operating profit of KRW 486.7 billion - Company exp...
First quarter revenue was $10.36 billion. First quarter GAAP diluted earnings per share (EPS) grew 15% to $3.98. First quarter adjusted EPS gre...
As Asia accounts for nearly half of the world’s cancer burden, the push toward precision medicine is more critical than ever. In this...
Will Tariffs Hit Pharmaceuticals? The Calm Before the Storm While the pharmaceutical industry may have narrowly escaped the latest wave of U.S. ta...
Croda is pleased to announce the appointments of Stephen Oxley as Chief Financial Officer (CFO) and Executive Director, and Dr. Thomas Riermeier as Presi...
WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025 Revenue grew 9.6% YoY to RMB 18,675.4 million, with ...
Aragen, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced two senior level appointments. Dr. Manjunath Rama...
Key Financial Highlights: Full-year net sales increased to €21.2 billion (organically: +2.0%) EBITDA pre rose to €6.1 billion (orga...
Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billion Fourth Quarter 2024 Net Loss of $31.3 million, de...
Appointment of three internal senior executives ensures strategic continuity with a new era of leadership Jean-Charles Wirth to become CEO Life Scienc...
Artificial intelligence is reshaping oncology, and ImpriMed is at the forefront of this transformation. With its AI-powered Personalized Prediction Profi...
AstraZeneca delivered $54.1 billion in total revenue for FY 2024, a 21% increase at constant exchange rates (CER), fueled by strong growth across oncolog...
© 2025 Biopharma Boardroom. All Rights Reserved.
